RELATIVITY-047 4-Year Update: Long-Term Outcomes in Frontline Metastatic Melanoma

Translating RELATIVITY-020 Part E Dosing Insights to Clinical Practice

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable responses, insights from the RELATIVITY-020 trial supporting standard-dose relatlimab due to its safety and efficacy balance, and emerging LAG-3 agents such as fianlimab that may influence future therapeutic strategies.

RELATIVITY-047 4-Year Update: Long-Term Outcomes in Frontline Metastatic Melanoma

Panelists discuss evolving frontline treatment strategies for metastatic melanoma, emphasizing recent clinical updates—particularly 4-year data from the RELATIVITY-047 trial—and exploring how these findings, including the benefits of nivolumab plus relatlimab, inform real-world decision-making for complex cases like BRAF-mutant disease with high tumor burden.